Skip to main content
Top
Published in: BMC Infectious Diseases 1/2002

Open Access 01-12-2002 | Hypothesis

Immunity status against poliomyelitis in Germany: Determination of cut-off values in International Units

Authors: Sabine Diedrich, Hermann Claus, Eckart Schreier

Published in: BMC Infectious Diseases | Issue 1/2002

Login to get access

Abstract

Background

To prevent importations of wild polioviruses into a polio free region a high level of population immunity must be kept. Standard methodology for determination of polio antibodies is a feature aimed at obtaining consistent results. An International Standard Serum for polio antibodies exists, but no protective level in International Units is defined.

Methods

A representative study was carried out in order to determine the serological status against poliomyelitis in Germany (n = 2564, age 18–79 years). Furthermore, sera from persons aged less than 18 years were included (n = 881). Microneutralization test has been used for determination of antibody levels. Results have been expressed in International Units.

Results

The results of this study indicate that the cut-off level for polio antibodies is 0.075 IU/ml for Polio 1, 0.180 IU/ml for Polio 2 and 0.080 IU/ml for Polio 3. Neutralizing antibodies against poliovirus type 1, 2 and 3 were detected in 96.2%, 96.8% and 89.6% of samples, respectively.

Conclusions

Overall, this seroprevalence indicates a very high level of immunity of the general population. It must be kept after the switch of immunization strategy from attenuated to inactivated vaccine in Germany.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schrope M: Plans to eradicate polio hit by virus outbreak in Bulgaria. Nature. 2001, 411: 405-10.1038/35078219.CrossRefPubMed Schrope M: Plans to eradicate polio hit by virus outbreak in Bulgaria. Nature. 2001, 411: 405-10.1038/35078219.CrossRefPubMed
2.
go back to reference Wood DJ, Heath AB: Comparability of poliovirus neutralizing antibody tests. Biologicals. 1992, 20: 293-300.CrossRefPubMed Wood DJ, Heath AB: Comparability of poliovirus neutralizing antibody tests. Biologicals. 1992, 20: 293-300.CrossRefPubMed
3.
go back to reference Wood DJ, Heath AB: The Second International Standard for Anti-Poliovirus Sera Types 1, 2 and 3. Biologicals. 1992, 20: 203-211.CrossRefPubMed Wood DJ, Heath AB: The Second International Standard for Anti-Poliovirus Sera Types 1, 2 and 3. Biologicals. 1992, 20: 203-211.CrossRefPubMed
4.
go back to reference Bellach BM, Knopf H, Thefeld W: Der Bundes-Gesundheitssurvey 1997/98. Das Gesundheitswesen. 1998, 60: S59-S68.PubMed Bellach BM, Knopf H, Thefeld W: Der Bundes-Gesundheitssurvey 1997/98. Das Gesundheitswesen. 1998, 60: S59-S68.PubMed
5.
go back to reference WHO: Poliovirus neutralizing antibody assay. Bull WHO. 1992, 70: 669- WHO: Poliovirus neutralizing antibody assay. Bull WHO. 1992, 70: 669-
6.
go back to reference WHO: Manual for the virological investigation of polio. WHO/EPI/GEN/97.01. 44-51. 1997 WHO: Manual for the virological investigation of polio. WHO/EPI/GEN/97.01. 44-51. 1997
7.
go back to reference Update: Outbreak of poliomyelitis – Dominican Republic and Haiti, 2000–2001. MMWR. 1997, 50: 855-856. Update: Outbreak of poliomyelitis – Dominican Republic and Haiti, 2000–2001. MMWR. 1997, 50: 855-856.
8.
go back to reference Mastroeni I, Patti AM, Fabrizi A, Santi AL, Manduca AM, Vescia N, et al: Immunity status against poliomyelitis in persons 13–14 years old living in Rome. Vaccine. 1997, 15: 747-750. 10.1016/S0264-410X(96)00208-3.CrossRefPubMed Mastroeni I, Patti AM, Fabrizi A, Santi AL, Manduca AM, Vescia N, et al: Immunity status against poliomyelitis in persons 13–14 years old living in Rome. Vaccine. 1997, 15: 747-750. 10.1016/S0264-410X(96)00208-3.CrossRefPubMed
9.
go back to reference Conyn-van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T: Immunity to poliomyelitis in the Netherlands. Am J Epidemiol. 2001, 153: 207-214. 10.1093/aje/153.3.207.CrossRefPubMed Conyn-van Spaendonck MA, de Melker HE, Abbink F, Elzinga-Gholizadea N, Kimman TG, van Loon T: Immunity to poliomyelitis in the Netherlands. Am J Epidemiol. 2001, 153: 207-214. 10.1093/aje/153.3.207.CrossRefPubMed
10.
go back to reference Diedrich S, Schreier E: Immunitätslage gegen Poliomyelitis (Polio-Serosurvey 1993)]. Dtsch Med Wochenschr. 1995, 120: 239-244.CrossRefPubMed Diedrich S, Schreier E: Immunitätslage gegen Poliomyelitis (Polio-Serosurvey 1993)]. Dtsch Med Wochenschr. 1995, 120: 239-244.CrossRefPubMed
11.
go back to reference Stark K, Schonfeld C, Barg J, Molz B, Vornwald A, Bienzle U: Seroprevalence and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin, Germany. Vaccine. 1999, 17: 844-850. 10.1016/S0264-410X(98)00269-2.CrossRefPubMed Stark K, Schonfeld C, Barg J, Molz B, Vornwald A, Bienzle U: Seroprevalence and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin, Germany. Vaccine. 1999, 17: 844-850. 10.1016/S0264-410X(98)00269-2.CrossRefPubMed
12.
go back to reference Franck S, Allwinn R, Rabenau HF, Doerr HW: Epidemiological analysis of immunity to poliovirus after termination of an era of vaccination with OPV in Germany. An analysis of the German Association Against Viral Diseases (DVV). Zentralbl Bakteriol. 1999, 289: 475-481.CrossRefPubMed Franck S, Allwinn R, Rabenau HF, Doerr HW: Epidemiological analysis of immunity to poliovirus after termination of an era of vaccination with OPV in Germany. An analysis of the German Association Against Viral Diseases (DVV). Zentralbl Bakteriol. 1999, 289: 475-481.CrossRefPubMed
13.
go back to reference Juhela S, Hyoety H, Lönnrot M, Roivainen M, Simell O, Ilonen J: Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol. 1998, 54: 226-232. 10.1002/(SICI)1096-9071(199803)54:3<226::AID-JMV14>3.3.CO;2-8.CrossRefPubMed Juhela S, Hyoety H, Lönnrot M, Roivainen M, Simell O, Ilonen J: Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol. 1998, 54: 226-232. 10.1002/(SICI)1096-9071(199803)54:3<226::AID-JMV14>3.3.CO;2-8.CrossRefPubMed
14.
go back to reference Fiore L, Ridolfi B, Genovese D, Buttinelli G, Lucioli S, Lahm A, et al: Poliovirus Sabin type 1 neutralization epitopes recognized immunoglobulin A monoclonal antibodies. Virol. 1997, 71: 6905-6912. Fiore L, Ridolfi B, Genovese D, Buttinelli G, Lucioli S, Lahm A, et al: Poliovirus Sabin type 1 neutralization epitopes recognized immunoglobulin A monoclonal antibodies. Virol. 1997, 71: 6905-6912.
15.
go back to reference Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T: Poliovirus-Specific Intestinal Antibody Responses Coincide with Decline of Poliovirus Excretion. J Infect Dis. 2000, 182: 1-5. 10.1086/315684.CrossRefPubMed Valtanen S, Roivainen M, Piirainen L, Stenvik M, Hovi T: Poliovirus-Specific Intestinal Antibody Responses Coincide with Decline of Poliovirus Excretion. J Infect Dis. 2000, 182: 1-5. 10.1086/315684.CrossRefPubMed
16.
go back to reference Oostvogel PM, Rumke HC, Conyn-van Spaendonck MA, van der Avoort HG, Leeuwenburg J, van Loon AM: Poliovirus circulation among schoolchildren during the early phase of the 1992–1993 poliomyelitis outbreak in The Netherlands. J Infect Dis. 2001, 184: 1451-1455. 10.1086/324327.CrossRefPubMed Oostvogel PM, Rumke HC, Conyn-van Spaendonck MA, van der Avoort HG, Leeuwenburg J, van Loon AM: Poliovirus circulation among schoolchildren during the early phase of the 1992–1993 poliomyelitis outbreak in The Netherlands. J Infect Dis. 2001, 184: 1451-1455. 10.1086/324327.CrossRefPubMed
Metadata
Title
Immunity status against poliomyelitis in Germany: Determination of cut-off values in International Units
Authors
Sabine Diedrich
Hermann Claus
Eckart Schreier
Publication date
01-12-2002
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2002
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-2-2

Other articles of this Issue 1/2002

BMC Infectious Diseases 1/2002 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine